Exact Sciences analyst focus on estimates, shares under Wall Street scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 16:06.

Exact Sciences (US30063P1057) remains in focus on the NASDAQ as analysts update their earnings models after a volatile start to 2026. The current consensus still expects narrowing losses and rising sales in coming quarters, according to data compiled by MarketBeat and MarketScreener.

What recent earnings showed

Exact Sciences last reported quarterly numbers for Q4 2025 on 13 February 2026, posting a loss per share of -0.21 dollars, well below the analyst consensus of a positive 0.08 dollars per share at the time, according to MarketBeat data covering Exact Sciences earnings. The miss of 0.29 dollars per share underlined the earnings volatility that still characterizes the diagnostics specialist.

Revenue in that Q4 2025 report continued to grow versus the prior year, driven by demand for colorectal cancer screening and other precision oncology tests, as outlined in the company’s earnings materials and investor commentary. The combination of top-line growth and negative earnings keeps the valuation and profitability trajectory central for NASDAQ investors who compare the group with peers such as Guardant Health and Illumina in the broader diagnostics and genomics segment.

How analysts currently rate Exact Sciences

Across Wall Street, most analysts still maintain positive recommendations on Exact Sciences, although target prices and ratings have been adjusted after the February 2026 earnings miss, according to aggregated data from MarketScreener and similar platforms that compile broker opinions on the EXAS ticker. Several major US brokers, including banks active in healthcare coverage such as JPMorgan and Citi, continue to model improving margins over the medium term even as they refine near-term EPS estimates.

The current consensus, as reflected in these data sets, points to further revenue growth in 2026 and 2027 alongside shrinking but still negative earnings per share for Exact Sciences. This implies that many analysts expect the company to continue investing heavily in research, development and commercial expansion while gradually moving its diagnostics portfolio closer to sustained profitability, a path that investors on NASDAQ often compare with trajectories seen at other high-growth life sciences names.

The diagnostics products behind the revenue

Exact Sciences generates most of its revenue with cancer screening and diagnostic tests, in particular the Cologuard stool DNA test for colorectal cancer that is marketed as a non-invasive alternative to colonoscopy in the United States, according to the company’s product information on its website. Further growth areas include liquid biopsy and genomic profiling tests in oncology, where the group aims to expand indications and reimbursement coverage through clinical data and partnerships.

Where Exact Sciences shares trade today

Exact Sciences shares (US30063P1057) trade on the NASDAQ in US dollars; the most recently available price data from major quote providers show the EXAS ticker changing hands on US exchanges with a market capitalization in the mid-single-digit billion dollar range, based on late-June 2026 trading snapshots.

This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any financial instrument. Figures and assessments are based on sources cited and may change without notice.